Medical Condition News

RSS

Radiologists discuss ways to reduce patient exposure, cancer risk

USA Today: "Doctors are exploring ways to reduce the amount of radiation exposure from medical imaging tests in light of renewed concerns about the cancer risk, according to research presented at a radiology conference this week.

6 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

Study: Hospital follow up can curb readmission rate for heart patients

"Hospitals can slow the revolving door that shuttles heart failure patients back into bed within a month of going home by following up promptly to ensure patients get the right outpatient care, a study shows," USA Today reports.

6 May 2010

Alcohol consumption during pregnancy can increase risk of AML in children

Although acute myeloid leukemia (AML) is relatively rare in children, drinking alcohol during pregnancy could increase the risk, according to a recent paper published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Positive results from Phase IIa clinical study of LIPO-102

Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.

6 May 2010

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.

6 May 2010

Use of combined PET/CT can confirm suspected colorectal cancer recurrence at early stage: Study

The use of combined positron emission tomography and computed tomography can confirm a suspected colorectal cancer recurrence at an early stage, helping significantly in treatment planning and improved targeted patient care, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

6 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

New research suggests tPA can act as neuroprotectant against stroke

New research on the properties of the clot-busting stroke drug tPA (tissue-type plasminogen activator) suggests that tPA can act as a neuroprotectant and may form the keystone of an adaptive response to a reduction in blood flow.

6 May 2010

New test indicates bone marrow cell therapy may benefit MS patients

A groundbreaking trial to test bone marrow stem cell therapy with a small group of patients with multiple sclerosis (MS) has been shown to have possible benefits for the treatment of the disease.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

DGIMED ORTHO, Inc. announced today that the company has received notification of clearance of its 510(k) submission for the DISTALOCKTM Titanium Femoral Intramedullary Nail system. In November 2009, the Company also received its initial clearance on the DISTALOCKTM Drill system with a stainless steel femoral IM nail.

6 May 2010

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

According to a new survey conducted by The National Heart Foundation, the forbidding ambulance costs are preventing timely calls to the emergency by at least one in 10 heart attack victims. The Foundation also released a discussion paper released during Heart Week urging free universal ambulance services in all states and territories. Dr Bill Coote in the paper entitled Universal Ambulance Cover has also said that this would prevent many heart attack deaths.

5 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Spouses of dementia sufferers at higher risk of developing dementia

Older married adults whose spouse has dementia are at significantly higher risk for developing dementia themselves, compared to similar older married adults whose spouse never develops dementia. This is the key finding of a study published today in the Journal of the American Geriatrics Society.

5 May 2010

Single night of partial sleep deprivation induces insulin resistance in healthy people

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

5 May 2010

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.

5 May 2010

Medical Condition News

Radiologists discuss ways to reduce patient exposure, cancer risk

New study reveals facial skin cancer occurs predominantly on left-side

Study: Hospital follow up can curb readmission rate for heart patients

Alcohol consumption during pregnancy can increase risk of AML in children

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Positive results from Phase IIa clinical study of LIPO-102

Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416

Use of combined PET/CT can confirm suspected colorectal cancer recurrence at early stage: Study

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

New research suggests tPA can act as neuroprotectant against stroke

New test indicates bone marrow cell therapy may benefit MS patients

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

DGIMED ORTHO receives 510(k) clearance for DISTALOCK Titanium Femoral Intramedullary Nail system

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Rockwell Medical first-quarter sales up 17.1%

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Spouses of dementia sufferers at higher risk of developing dementia

Single night of partial sleep deprivation induces insulin resistance in healthy people

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News